You may leave me a review on these links:

Dr Malinda Itchins

  • BMedSci, MBBS (Hons1), FRACP, PhD
  • Medical Oncologist
  • Spoken languages English


Looking after people at the most vulnerable time in their lives whilst navigating a cancer diagnosis is a privilege.

Awards received

  • Inaugural NSW Health PhD Scholarship 2017-2020
  • Pfizer ANZ Clinical Trial Medical Grant 2017-2022
  • Fight for a Cure Translational Research Grant 2019
  • Sydney Vital Research Scholar Awards 2018, 2019

Research interests

  • Understanding mechanisms of, and strategies to prevent, drug resistance in molecularly driven lung cancers
  • Maximising diagnostics and the multidisciplinary team treatment approach in lung and pancreatic cancer

Publications and affiliations

  • Itchins M et al. Precision Medicine Clinic: Molecular Tumor Board ALK-rearranged non-small cell lung cancer in 2020: Real-world triumphs in an era of multi-generation ALK-inhibitor sequencing informed by drug resistance profiling. The Oncologist. 2020;25(8)641-649
  • Alexander M… Itchins M. A multicenter study of thromboembolic events among patients diagnosed with ROS1-rearranged non-small cell lung cancer. Lung Cancer. 2020;142:34-40
  • Itchins M et al. Pattern of Care and Survival of Anaplastic Lymphoma Kinase Rearranged Non-Small Cell Lung Cancer (ALK+ NSCLC) in an Australian Metropolitan Tertiary Referral Centre. A Retrospective Cohort Analysis. Asia Pac J Clin Oncol. 2018;14(5):e275-82
  • Itchins M et al. Treatment of ALK-rearranged non-small cell lung cancer – a review of the landscape and approach to emerging patterns of treatment resistance in the Australian context. Asia Pac J Clin Oncol. 2017; 13:3-13
  • Itchins M et al. Retrospective cohort analysis of neoadjuvant treatment and survival in resectable and borderline resectable pancreatic ductal adenocarcinoma in a high-volume referral centre. Eur J Surg Oncol. 2017; 43(9):1711-7

Professional memberships

  • Thoracic Oncology Group of Australasia (TOGA)- Early Career Representative, Scientific Committee
  • Clinical Oncology Society of Australia (COSA)- Lung Cancer Chair
  • International Association for the Study of Lung Cancer (IASLC) Member
  • Australasian Gastrointestinal Trials Group (AGITG) Member